This checklist is for Princeton-area individuals, families, and support networks assessing ibogaine-related claims. It does not endorse a provider, recommend treatment, or suggest pursuing unlawful care. Begin with the wider ibogaine due-diligence overview if you need a grounded starting point for questions about claims, evidence, legality, and risk.
Featured guide
Ask for records, not reassurance.
A credible answer should be specific enough to check: a registration number, a written protocol, a licensing record, a monitoring plan, or a stated transfer pathway.
Start with the legal and research status.
Ask whether the offering is presented as a regulated clinical trial, a lawful service in another jurisdiction, or something else. Do not rely on labels alone. Ibogaine is listed as a Schedule I controlled substance in the United States under the DEA’s drug scheduling framework, so descriptions of availability should be checked carefully against the relevant law and setting.
If a provider says participation is part of a study, request the exact clinical trial registration number and the IRB information. A trial record can be searched through ClinicalTrials.gov; absence from a public record is not, by itself, a complete legal conclusion, but it is a reason to ask more precise questions rather than assume oversight.
For a separate discussion of the questions to raise about local legal claims, consult the site’s Princeton legal-status guide. Cross-border arrangements can involve more than one jurisdiction, and neither advertising language nor a testimonial resolves that complexity.
Verify who is accountable and what governs care.
Request the written protocol and the stopping rules: what screening occurs, what findings would exclude someone, when treatment would be paused or stopped, and who has authority to make those decisions. If the program invokes an investigational pathway, ask how the protocol and IRB oversight apply to the particular setting.
Ask for clinician names, professional roles, licensing jurisdictions, and the practical scope of each person’s work. Then check licensure and disciplinary history through the relevant official board or regulator, rather than accepting a profile at face value. The Federation of State Medical Boards directory can help identify the appropriate U.S. state medical board when that is relevant.
Search for peer-reviewed publications separately from provider marketing. A publication can show that a paper exists; it does not automatically validate every protocol, outcome claim, or service being offered. The broader approach to evidence scrutiny is also reflected in the project’s stated principles.
- Trial or authorization numberAsk for the exact identifier, not a general statement that research is involved.
- Written protocolRequest screening criteria, exclusions, stopping rules, and follow-up plans.
- Named licensed rolesClarify who supervises care and which jurisdiction recognizes each license.
- Independent oversightAsk what IRB or regulatory process applies and how concerns can be raised.
Ask about cardiac monitoring and emergency response.
Safety conversations should be concrete. Ask what cardiac screening is used, what monitoring equipment is available during care, who is present, and whether a licensed physician and ACLS-certified staff are on site when their roles are needed. Ask how the team handles medication interactions, changes in condition, and a need to stop the process.
Request a clear emergency-transfer plan: the destination facility, how transfer is initiated, who accompanies the person, and what clinical information travels with them. A general assurance that “help is nearby” is not the same as a usable plan. For background on why rhythm-related questions deserve direct attention, see the site’s discussion of ibogaine safety and risk considerations.
The term advanced cardiovascular life support describes a formal approach to urgent cardiovascular care; an ACLS claim should prompt follow-up about current certification, staffing coverage, equipment, and the limits of the setting. This is not a substitute for individualized medical advice.
Read informed consent before any payment or travel plan.
Request the informed-consent documents early enough to read them without pressure. They should identify specific risks, screening limits, possible interactions, alternatives, foreseeable aftercare needs, and what happens if a person withdraws or requires escalation. A document is meaningful only if there is time to ask questions and receive direct answers.
Compare the stated risks with the provider’s public claims. Guaranteed results, broad claims of safety, or language that dismisses known uncertainty should be treated as reasons to pause. A useful review also asks whether the same named organization is responsible for screening, acute care, transport coordination, and follow-up—or whether those functions are separated without a clear handoff.
Keep the standard simple: if a claimed safeguard cannot be described, documented, and independently checked, it should not be counted as established.
Notice what a provider will not show you.
Red flags include claims of guaranteed results, refusal to share a protocol or explain stopping rules, pressure to decide quickly, vague answers about monitoring, and cash-only underground operations that cannot provide verifiable legal or clinical information. These signals do not establish every fact about a provider, but they are reasons not to fill gaps with optimism.
Search disciplinary records where possible and look beyond testimonials. A provider’s own materials are not an independent source. Some Princeton-area readers may find it helpful to compare questions with resources focused on particular communities, including military-oriented ibogaine due-diligence information, while still applying the same checks to legal status, evidence, credentials, and emergency planning.
Keep a local care path available.
Before considering travel or any provider claim, consider local linkage with a licensed clinician or established addiction and mental-health service that can assess current needs, medications, risks, and lawful options. A local professional may not endorse ibogaine and should not be expected to do so; the point is to preserve access to ordinary care and crisis support.
For a concise map of the resource’s information categories and question-led materials, see the available guidance topics. When immediate safety is a concern, seek emergency help through local emergency services rather than relying on a remote provider’s marketing or an online checklist.
Questions worth keeping open.
What should a provider share before anyone makes a decision?
A provider should be able to share its trial registration or authorization information where applicable, its written protocol and stopping rules, the roles and licensure of the care team, cardiac monitoring arrangements, emergency-transfer planning, and informed-consent documents.
What are practical red flags?
Red flags include guaranteed-result claims, refusal to share a protocol or discuss safety limits, pressure to decide quickly, and cash-only underground operations that cannot provide verifiable legal or clinical information.
What can local care linkage look like?
Local linkage can begin with a licensed clinician or established addiction and mental-health service able to assess current needs, medication risks, and lawful options. This resource does not endorse treatment or individual providers.
Bring the questions, not assumptions.
Write down what is claimed, what document supports it, and what remains unanswered. Slowing down is a valid safety step.